Abstract
One hundred and twenty-four patients who had had recurrent aphthous stomatitis (RAS) for two to 53 years took part in three studies to assess the effectiveness of levamisole and determine an adequate regimen. In study 1 and the first half of study 2 both of which were double-blind, levamisole 150 mg/day (or placebo) was given on three consecutive days in every fortnight. In the second two months of study 2 and in the open trial (study 3) three-day courses were given only when an episode of RAS occurred. The drug was well tolerated. The signs and symptoms of RAS improved gradually and significantly in those treated with levamisole but not in those on placebo, and intergroup differences were also significantly in favour of the active drug. Improvement occurred earlier in study 3 than in the other two studies. Hence levamisole may prevent new episodes of RAS.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brugmans J., Schuermans V., De Cock W., Thienpont D., Janssen P., Verhaegen H., Van Nimmen L., Louwagie A. C., Stevens E. Restoration of host defense mechanisms in man by levamisole. Life Sci. 1973 Dec 1;13(11):1499–1504. doi: 10.1016/0024-3205(73)90137-9. [DOI] [PubMed] [Google Scholar]
- Embil J. A., Stephens R. G., Manuel F. R. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J. 1975 Oct 4;113(7):627–630. [PMC free article] [PubMed] [Google Scholar]
- Symoens J., Brugmans J. Letter: Treatment of recurrent aphthous stomatitis and herpes with levamisole. Br Med J. 1974 Dec 7;4(5944):592–592. doi: 10.1136/bmj.4.5944.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Verhaegen H., De Cree J., Brugmans J. Letter: Treatment of aphthous stomatitis. Lancet. 1973 Oct 13;2(7833):842–842. doi: 10.1016/s0140-6736(73)90879-9. [DOI] [PubMed] [Google Scholar]